Zhong Ji Longevity Science Announces 2021 Interim Results
Retrieved on:
Tuesday, August 31, 2021
Cloud, MOU, Science, Research, Health, Awareness, Board, Risk, Partnership, Solution, Longevity, Seemabaddha, Ecosystem, Thermo Fisher Scientific, Health care, Vitamin C, Software, China Biologic Products, Consultant, Master, Investment, Martin Yan, VC, Nobel Prize in Physiology or Medicine, Technology, Industry, MSC, Incidence, Review, R, The Group, Tablet, NK, Biotechnology, Mortality, FDA, NMN, Growth, Cancer, Acquisition, Period, Marketing, National Healthcareer Association, CBNK, COVID-19, Property management, Management, Pharmaceutical industry
HONG KONG, Aug 31, 2021 - (ACN Newswire) - Zhong Ji Longevity Science Group Limited ("Zhong Ji Longevity Science", together with its subsidiaries, the "Group"; stock code: 0767.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2021 ("Period under Review").
Key Points:
- HONG KONG, Aug 31, 2021 - (ACN Newswire) - Zhong Ji Longevity Science Group Limited ("Zhong Ji Longevity Science", together with its subsidiaries, the "Group"; stock code: 0767.HK) is pleased to announce its unaudited interim results for the six months ended 30 June 2021 ("Period under Review").
- Mr. YAN Li, Chairman of the Board and Executive Director of Zhong Ji Longevity Science, said, "Since the change of company name, the Group has been focusing on expanding its longevity science business.
- It is expected that longevity science industry will embrace bright prospects, leading the development of Zhong Ji Longevity Science to bear fruits in future.
- Zhong Ji Longevity Science Group Limited (0767.HK) is principally engaged in longevity science, money lending, securities and other investments, financial and investment advisory, as well as property investment.